The renin-angiotensin system and peritoneal dialysis

Peritoneal Dialysis International

Volumn 24, Issue 1, 2004, Pages 5-9

  Duman, Soner ^a   Breborowicz, Andrzej ^b  

^a EGE UNIVERSITY   (Turkey)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; AQUAPORIN 1; AQUAPORIN 4; BENAZEPRIL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRONECTIN; IMIDAPRIL; INTERLEUKIN 6; LAMININ; LISINOPRIL; LOSARTAN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEOGLYCAN; QUINAPRIL; RAMIPRIL; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VALSARTAN; VASCULOTROPIN;

APOPTOSIS; CELL PROLIFERATION; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETIC NEPHROPATHY; DRUG RECEPTOR BINDING; EDITORIAL; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; KIDNEY FIBROSIS; KIDNEY INJURY; NONHUMAN; PERITONEUM; PERITONITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION;

EID: 3042776225     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080402400101     Document Type: Editorial

References (49)

1. Gokal R. Taking peritoneal dialysis beyond the year 2000. Perit Dial Int 1999; 19(Suppl 3):S35-42.
2. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11:498-506.
3. Selgas R, Fernandez-Reyes M-J, Bosque E, Bajo M-A, Borrego F, Jimenez C, et al. Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective median long-term study. Am J Kidney Dis 1994; 23:64-73.
4. Heimbürger O, Waniewski J, Werynski A, Tranæus A, Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38:495-506.
5. Di Paolo N, Sacchi G. Atlas of peritoneal histology. Perit Dial Int 2000; 20(Suppl 3):S5-96.
6. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
7. Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72:171-6.
8. Rubin J, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991; 18: 97-102.
9. Fracasso A, Baggio B, Ossi E, Del Prete D, Bonfante L, Bazzato G, et al. Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis 1999; 33:105-10.
10. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14: 1541-9.
11. Chaimovitz C. Peritoneal dialysis. Kidney Int 1994; 45: 1226-40.
12. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12:14-27.
13. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001; 10:321-9.
14. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465-75.
15. Strutz F, Muller GA. Transdifferentiation comes of age. Nephrol Dial Transplant 2000; 15:1729-31.
16. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993; 3:1531-40.
17. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001; 38:635-8.
18. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57:601-6.
19. Border WA, Noble NA. TGF β in kidney fibrosis: a target for gene therapy. Kidney Int 1997; 51:1388-96.
20. Peters H, Border WA, Noble NA. Targeting TGF β overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1570-80.
21. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blonco J, Mezzano S, et al. ANG II also regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 2002; 82:S12-22.
22. Lods N, Ferrari P, Frey FJ, Kappeler A, Berthier C, Vogt B, et al. Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. J Am Soc Nephrol 2003; 14:2861-72.
23. Liu BC, Sun J, Chen Q, Ma KL, Ruan XZ, Phillips AO. Role of connective tissue growth factor in mediating hypertrophy of human proximal tubular cells induced by angiotensin II. Am J Nephrol 2003; 23:429-37.
24. Ma LJ, Yang H, Gaspert A, Carlesso G, Barty MM, Davidson JM, et al. Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol 2003; 163:1261-73.
25. Thomas DW, Hoffman MD. Identification of macrophage receptor for angiotensin: a potential role in antigen uptake for T lymphocyte responses? J Immunol 1984; 132:2807-12.
26. Lagna G, Hata A, Massagué J. Partnership between DPC4 and SMAD protein in TGF-beta signalling pathways. Nature 1996; 383:832-6.
27. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, et al. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001; 88:22-9.
28. Rizkalla B, Forbes JM, Cooper ME, Cao Z. Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 2003; 14: 3061-71.
29. Yao Q, Lindholm B, Qian J. Inhibition of the effect of high glucose (HG) on the expression of Smad in human peritoneal mesothelial cells [Abstract]. J Am Soc Nephrol 2003; 14:215A.
30. Noh H, Kim HJ, Yu MR, Ha H, Lee HB. Renin angiotensin system in human peritoneal mesothelial cells [Abstract]. J Am Soc Nephrol 2003; 14:218A.
31. Sawada T, Ishii Y, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S. The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. Pharmacol Res 2002; 46:505-10.
32. Abe K, Miyazaki M, Yoshio Y, Furusu A, Harada T, Sugaya T, et al. Importance of angiotensin II type 1 receptor in bone marrow derived cells in the progression of peritoneal fibrosis [Abstract]. J Am Soc Nephrol 2003; 14:36A.
33. Imai H, Nakamoto H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, et al. Renin-angiotensin system plays an important role in the regulation of water transport in the peritoneum. Adv Perit Dial 2001; 17:20-4.
34. Duman S, Gunal AI, Sen S, Asci G, Ozkahya M, Terzioglu E, et al. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 2001; 21:219-24.
35. Duman S, Şen S, Aşçi G, Başçi A, Akçiçek F. Effect of valsartan versus lisinopril on peritoneal alterations in rats [Abstract]. Perit Dial Int 2002; 22:112.
36. Duman S, Şen S, Duman C, Aşci G, Basci A, Akcicek F. Improvement of peritoneal alterations induced by hypertonic PD solutions by ACE inhibitors and by AR blockers [Abstract]. Nephrol Dial Transplant 2003; 18(Suppl 4):s474.
37. Agraharkar M, Du Y, Man-Wan C, Henry S, Kuo YF, Ahuja T. Angiotensin II receptor blockade (ARB) and peritoneal protein loss in peritoneal dialysis patients [Abstract]. J Am Soc Nephrol 2003; 14:858A.
38. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patient with diabetic nephropathy. Kidney Int 2000; 57:601-6.
39. Bauer JH, Reams GP, Hewett J, Klachko D, Lau A, Messina C, et al. A randomized, double blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 1992; 20:443-57.
40. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352:1252-6.
41. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354:359-64.
42. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139:105-12.
43. Kikuta T, Watanabe Y, Kanno Y, Tomori K, Nakamoto H, Okada H, et al. Effects of angiotensin II-receptor blocker, valsartan, on residual renal function in patients on CAPD [Abstract]. J Am Soc Nephrol 2003; 14:482A.
44. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93:2431-7.
45. Fava S, Azzopardi J, Ellard S, Hattersley AT. ACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease. Diabetes Care 2001; 24:2115-20.
46. Azar ST, Zalloua PA, Medlej R, Halabi G. The DD genotype of the ACE gene polymorphism is associated with diabetic nephropathy in the type-1 diabetics. Endocr Res 2001; 27:99-108.
47. Nishina M. A study on angiotensin-I converting enzyme polymorphism in CAPD patients. Nippon Jinzo Gakkai Shi 1996; 38:595-602.
48. Wang AY, Chan JC, Wang M, Poon E, Lui SF, Li PK, et al. Cardiac hypertrophy and remodeling in relation to ACE and angiotensinogen genes genotypes in Chinese dialysis patients. Kidney Int 2003; 63:1899-907.
49. Varagunam M, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM. Angiotensin-converting enzyme gene polymorphism and erythropoietin requirement. Perit Dial Int 2003; 23:111-15.